Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14, SHA:600329) plans to provide guarantees of up to a total of 2.46 billion yuan to affiliates Tianjin Pharmaceutical Group Taiping Medicine and Tianjin Zhongxin Medicine, according to a Friday filing on the Singapore Exchange.
The proposed guarantees, subject to shareholder approval, align with the company's 43.35% stake in Taiping Medicine.
The move aims to support the two firms' financing needs, but investors are cautioned as both entities have asset-liability ratios exceeding 70%.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。